Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+T cells in African adults

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+T cells in African adults

Show other versions (1)

Addressing HIV-1 variability is a major scientific challenge, because vaccine-induced immune responses must recognize multiple HIV-1 variants. One approach focuses on conserved HIV-1 sequences that are common to majority of variants and cannot easily mutate. We tested HIV-1 prime-boost vaccine regim...

Full description

Bibliographic Details
Main Authors:	Cox, J, Farah, B, Langat, R, Indangasi, J, Ogola, S, Onsembe, B, Kopycinski, J, Hayes, P, Borthwick, N, Barin, B, Gilmour, J, De Bont, J, Anzala, O, Fast, P, Reilly, M, Chinyenze, K, Mutua, G, Jaoko, W, Hanke, T, Grp, H
Format:	Conference item
Published:	Mary Ann Liebert 2016

Similar Items

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults
by: Mutua, G, et al.
Published: (2017)

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults
by: Gaudensia Mutua, et al.
Published: (2016-01-01)

Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya.
by: Gloria Omosa-Manyonyi, et al.
Published: (2014-01-01)

Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
by: Mutua, G, et al.
Published: (2012)

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
by: Jaoko, W, et al.
Published: (2008)

Targeting HIV-1 where it hurts
by: Borthwick, N, et al.
Published: (2013)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1
by: Borthwick, N, et al.
Published: (2014)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.
by: Borthwick, N, et al.
Published: (2014)

Development of Broadly Neutralizing Antibody Responses in a Large Sub-Sahara African HIV Primary Infection Cohort
by: Landais, E, et al.
Published: (2013)

Early antiretroviral therapy and its impact on natural killer cell dynamics in HIV-1 infected men who have sex with men: a cross-sectional pilot study evaluating the impact of early ART initiation on NK cell perturbation in HIV infection
by: Matrona Akiso, et al.
Published: (2024-04-01)

AIDS vaccines and preexposure prophylaxis: is synergy possible?
by: Excler, J, et al.
Published: (2011)

Performance of International AIDS Vaccine Initiative African clinical research laboratories in standardised ELISpot and peripheral blood mononuclear cell processing in support of HIV vaccine clinical trials
by: Robert K. Langat, et al.
Published: (2021-02-01)

Stabilized coronavirus spike stem elicits a broadly protective antibody
by: Ching-Lin Hsieh, et al.
Published: (2021-11-01)

Targeting HIV-1 Where It Hurts
by: Ahmed, T, et al.
Published: (2013)

Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
by: Jakub Kopycinski, et al.
Published: (2014-01-01)

Optimizing immunization protocols to elicit broadly neutralizing antibodies
by: Sprenger, Kayla G, et al.
Published: (2021)

Specificity of CD8<sup>+</sup> T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya
by: Yehia S. Mohamed, et al.
Published: (2020-05-01)

Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies
by: Yousuf Ahmed, et al.
Published: (2017-09-01)

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
by: Peters, B, et al.
Published: (2007)

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers (vol 26, pg 6671, 2008)
by: Guimaraes-Walker, A, et al.
Published: (2011)

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens.
by: Nathifa Moyo, et al.
Published: (2017-01-01)

Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
by: Jeffrey Seow, et al.
Published: (2023-10-01)

Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.
by: Boaz, M, et al.
Published: (2009)

Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses
by: Naarding, M, et al.
Published: (2014)

Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses.
by: Naarding, M, et al.
Published: (2014)

Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses
by: Hills, RA, et al.
Published: (2024)

Enhancing capacity of research ethics review committees in developing countries: The Kenyan example
by: Gloria Manyonyi, et al.
Published: (2014-11-01)

Design of immunogens to elicit broadly neutralizing antibodies against HIV targeting the CD4 binding site
by: Conti, Simone, et al.
Published: (2021)

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
by: Moyo, N, et al.
Published: (2017)

Murine Leukemia-Derived Extracellular Vesicles Elicit Antitumor Immune Response
by: Pando A, et al.
Published: (2021-05-01)

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
by: Payton A.-B. Weidenbacher, et al.
Published: (2023-04-01)

Multiscale affinity maturation simulations to elicit broadly neutralizing antibodies against HIV
by: Simone Conti, et al.
Published: (2022-04-01)

Elicitation of broadly neutralizing antibodies against HIV-1 – the germline/maturation hypothesis
by: Prabakaran ePonraj, et al.
Published: (2014-08-01)

Baculovirus Displaying Hemagglutinin Elicits Broad Cross-Protection against Influenza in Mice.
by: Sang-Hee Sim, et al.
Published: (2016-01-01)

PedVacc Infant HIV-1 Vaccine Trials: First Stage Towards a Vaccine Against Breast Milk Transmission of HIV-1
by: Hanke, T, et al.
Published: (2011)

Understanding adherence to daily and intermittent regimens of oral HIV pre-exposure prophylaxis among men who have sex with men in Kenya
by: Mugo, PM, et al.
Published: (2014)

Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice.
by: Jiong Wang, et al.
Published: (2018-01-01)

A statistical approach to determining responses to individual peptides from pooled-peptide ELISpot data.
by: Ström, P, et al.
Published: (2016)

Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort.
by: Landais, E, et al.
Published: (2016)

A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response.
by: Graeme J M Cowan, et al.
Published: (2011-01-01)